Industrial Transformation Research Hubs - Grant ID: IH150100028
Funder
Australian Research Council
Funding Amount
$3,708,510.00
Summary
ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. This hub aims to improve detection of biological materials by building a portable device for rapid, time-critical detection of low-abundance molecular and cellular analytes. It is expected that the resulting technologies would be used at medical points of care, ordinary workplaces and centres of activity to test for tiny levels of targeted molecu ....ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. This hub aims to improve detection of biological materials by building a portable device for rapid, time-critical detection of low-abundance molecular and cellular analytes. It is expected that the resulting technologies would be used at medical points of care, ordinary workplaces and centres of activity to test for tiny levels of targeted molecules. The initial focus would be early diagnosis of disease and point-of-care drug testing for humans and animals, but the technology platform could be used to sample food and environmental toxins. The hub expects these disruptive technologies will make Australian biotechnology, diagnostics, veterinary, agribusiness and manufacturing firms globally competitive.Read moreRead less
Advanced biosensing in the terahertz (THz) sub-wavelength regime. This project will build on Australian excellence in photonics, exploiting the advanced use of T-rays for sensing of biological substances such as proteins and DNA. For the first time, this will enable contactless automated sensing for high-speed medical screening of diseases, a critical step toward the ultimate vision of customised medicine.
Electrochemical biosensors for detection of cardiac disease markers in blood. Cardiovascular diseases leading to heart failure have a prevalence of over 16 per cent in Australia. The social, economic and health burden is higher than for any other disease group. Hence, it is critically important to develop fit-for-purpose sensors of known cardiac biomarkers, which alert patients and clinicians of the risk of imminent heart failure.